Evidence map›Paper›PMID 34860848›Full record

Observational studyPloS one2021

Analysis of case fatality rate of SARS-CoV-2 infection in the Spanish Autonomous Communities between March and May 2020.

Martín-Sánchez V, Calderón-Montero A, Barquilla-García A, Vitelli-Storelli F, Segura-Fragoso A, Olmo-Quintana V, Serrano-Cumplido A, COVID-19 Group of the Spanish Society of Primary Care Physicians (SEMERGEN)

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Martín-Sánchez VResearch Group in Gene-Environment Interactions and Health, Institute of Biomedicine (IBIOMED), University of León, León, Spain.
Calderón-Montero ADoctor Pedro Laín Entralgo Health Center, Madrid Health Service (SERMAS), Alcorcón, Madrid, Spain.ORCID 0000-0002-3729-5944
Barquilla-García ATrujillo Health Center, Extremadura Health Service, Cáceres, Spain.
Vitelli-Storelli FResearch Group in Gene-Environment Interactions and Health, Institute of Biomedicine (IBIOMED), University of León, León, Spain.
Segura-Fragoso AHealth Science Department, Castilla La Mancha University, Talavera de la Reina, Toledo, Spain.
Olmo-Quintana VManagement Pharmacy Service Primary Health Care, Vicepresident of Ethical Committee Research with Medicine Hospital Dr. Negrín Gran Canaria Las Palmas (CEI/CEIm) Canary Health Service, Las Palmas, Spain.ORCID 0000-0002-6212-8478
Serrano-Cumplido AFamily and Community Medicine, Getxo, Bizkaia, Spain.
COVID-19 Group of the Spanish Society of Primary Care Physicians (SEMERGEN)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe Spanish health system is made up of seventeen regional health systems. Through the official reporting systems, some inconsistencies and differences in case fatality rates between Autonomous Communities (CC.AA.) have been observed. Therefore the objective of this paper is to compare COVID-19 case fatality rates across the Spanish CC.AA. MATERIAL AND

methodsObservational descriptive study. The COVID-19 case fatality rate (CFR) was estimated according to the official records (CFR-PCR+), the daily mortality monitory system (MoMo) record (CFR-Mo), and the seroprevalence study ENE-COVID-19 (Estudio Nacional de sero Epidemiologia Covid-19) according to sex, age group and CC.AA. between March and June 2020. The main objective is to detect whether there are any differences in CFR between Spanish Regions using two different register systems, i. e., the official register of the Ministry of Health and the MoMo.

resultsOverall, the CFR-Mo was higher than the CFR-PCR+, 1.59% vs 0.98%. The differences in case fatality rate between both methods were significantly higher in Castilla La Mancha, Castilla y León, Cataluña, and Madrid. The difference between both methods was higher in persons over 74 years of age (CFR-PCR+ 7.5% vs 13.0% for the CFR-Mo) but without statistical significance. There was no correlation of the estimated prevalence of infection with CFR-PCR+, but there was with CFR-Mo (R2 = 0.33). Andalucía presented a SCFR below 1 with both methods, and Asturias had a SCFR higher than 1. Cataluña and Castilla La Mancha presented a SCFR greater than 1 in any scenario of SARS-CoV-2 infection calculated with SCFR-Mo.

conclusionsThe PCR+ case fatality rate underestimates the case fatality rate of the SARS-CoV- 2 virus pandemic. It is therefore preferable to consider the MoMo case fatality rate. Significant differences have been observed in the information and registration systems and in the severity of the pandemic between the Spanish CC.AA. Although the infection prevalence correlates with case fatality rate, other factors such as age, comorbidities, and the policies adopted to address the pandemic can explain the differences observed between CC.AA.

Indexed as

COVID-19HumansPandemicsPrevalenceRegistriesSeroepidemiologic StudiesSpainSurvival Rate

Identifiers

PMID34860848
PMCPMC8641878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.